Sagimet (SGMT) CEO David Happel Sells 64,051 Shares

What Happened
David Happel, President & CEO and a director of Sagimet Biosciences (SGMT), disposed of 64,051 shares on July 20, 2026. The transaction generated approximately $497,068 in proceeds. The reported weighted-average price was $7.76; the shares were sold in multiple tranches at prices ranging from $7.76 to $7.94.

Key Details

• Transaction type: Sale (S) of 64,051 shares on 2026-07-20.
• Reported proceeds: ~$497,068; weighted-average price $7.76 (actual sales ranged $7.76–$7.94).
• Footnote F1: These sales were automatic and made to satisfy tax-withholding obligations arising from the vesting of restricted stock units (RSUs); not at the reporting person’s discretion.
• Footnote F2: The $7.76 is a weighted average; the filer can provide a breakdown of the number of shares sold at each specific price within the stated range upon request.
• Shares owned after the transaction: Not specified in the provided filing excerpt.
• Filing: Form 4 was filed on July 22, 2026 (two days after the transaction date), which is within the typical two-business-day reporting window.

Context
Sales to cover tax withholding on vested RSUs are common and typically routine; they do not necessarily indicate the insider’s view on the company’s prospects. For retail investors, purchases often carry more immediate informational weight than sales performed solely to satisfy tax obligations.